Redhill Biopharma Stock Today
| RDHL Stock | USD 3.65 0.60 14.12% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Redhill Biopharma is selling for 3.65 as of the 26th of February 2025. This is a 14.12 percent decrease since the beginning of the trading day. The stock's lowest day price was 3.65. Redhill Biopharma has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 4th of November 2023 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 7th of January 2013 | Category Healthcare | Classification Health Care |
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel. Redhill Biophrma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 1.3 M outstanding shares of which 5.33 K shares are at this time shorted by private and institutional investors with about 0.48 trading days to cover. More on Redhill Biopharma
Moving together with Redhill Stock
Moving against Redhill Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Redhill Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman of the Board, CEO | Dror BenAsher | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Name | RedHill Biopharma Ltd | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsRedhill Biopharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Redhill Biopharma's financial leverage. It provides some insight into what part of Redhill Biopharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Redhill Biopharma (RDHL) is traded on NASDAQ Exchange in USA. It is located in 21 Ha?arba?a Street, Tel Aviv, Israel, 6473921 and employs 53 people. Redhill Biopharma is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.52 M. Redhill Biopharma conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 1.3 M outstanding shares of which 5.33 K shares are at this time shorted by private and institutional investors with about 0.48 trading days to cover.
Redhill Biopharma currently holds about 28.86 M in cash with (35.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55.
Check Redhill Biopharma Probability Of Bankruptcy
Ownership AllocationRoughly 93.3 pct. of Redhill Biopharma outstanding shares are held by general public with 6.7 (%) by third-party entities.
Check Redhill Ownership Details
Redhill Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Wells Fargo & Co | 2024-09-30 | 0.0 | |
| Sabby Management Llc | 0.0 | ||
| Jane Street Group Llc | 2024-09-30 | 0.0 | |
| Citadel Advisors Llc | 2024-09-30 | 0.0 | |
| Capital Performance Advisors Llp | 2024-12-31 | 0.0 | |
| Jpmorgan Chase & Co | 2024-09-30 | 0.0 | |
| F.l.putnam Investment Management | 2024-09-30 | 0.0 | |
| Virtu Financial Llc | 2024-09-30 | 0.0 | |
| Ifp Advisors, Llc | 2024-12-31 | 0.0 | |
| Gamma Investing Llc | 2024-12-31 | 5.1 K | |
| Ubs Group Ag | 2024-12-31 | 4.4 K |
Redhill Biopharma Historical Income Statement
Redhill Stock Against Markets
Redhill Biopharma Corporate Management
| Reza Fathi | Senior Development | Profile | |
| Kristin Comer | G VP | Profile | |
| Valerie Graceffa | VP Sales | Profile | |
| Razi Ingber | Chief Officer | Profile | |
| Rob Jackson | VP Marketing | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share | Quarterly Revenue Growth (0.28) | Return On Assets | Return On Equity |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.